Tumor Biology

, Volume 36, Issue 2, pp 1233–1236 | Cite as

Investigation of circulating antibodies to ANXA1 in breast cancer

  • Yile Huang
  • Cong Zhang
  • Cairen Chen
  • Shilong Sun
  • He Zheng
  • Shuli Wan
  • Qingyong Meng
  • Yubin Chen
  • Jun Wei
Research Article

Abstract

Our recent work demonstrated that circulating levels of IgG antibody to linear peptide antigens derived from annexin A1 (ANXA1) were significantly increased in lung cancer. The present study was then undertaken to test whether circulating anti-ANXA1 antibodies were also altered in breast cancer. An enzyme-linked immunosorbent assay was developed in-house to determine circulating IgG against ANXA1-derived peptide antigens in 152 female patients with breast cancer and 160 female control subjects. Student’s t test revealed that patients with breast cancer had significantly higher levels of anti-ANXA1 IgG than control subjects (t = 4.75, P < 0.0001). Receiver operating characteristic (ROC) analysis showed that the area under the ROC curve was 0.73 with 95 % confidence interval (CI) 0.67–0.78, and the sensitivity of anti-ANXA1 IgG assay was 23.2 % against the specificity of 90 %. The levels of anti-ANXA1 IgG did not appear to be stage-dependent, and Pearson correlation analysis showed no correlation between the anti-ANXA1 IgG levels and the stages of breast cancer (r = −0.02, df = 149, P = 0.796). This work suggests that circulating IgG for ANXA1-derived peptide antigens may have both diagnostic and prognostic values for breast cancer although further screening is needed to identify more such peptide antigens derived from tumor-associated antigens.

Keywords

Autoantibody ANXA1 Breast cancer Tumor immunity 

Notes

Acknowledgments

We thank all the patients and control subjects for their participation in this study. We also thank the Third Affiliated Hospital of Harbin Medical University, Harbin, China, for the recruitment of patients with breast cancer. This work was supported by YingJi Biotechnology Exploitation Co. Ltd., Shenzhen, China, and by Glory Biomedical Co. Ltd., Taipei, Taiwan.

Conflicts of interest

None

References

  1. 1.
    DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.CrossRefPubMedGoogle Scholar
  2. 2.
    Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620. doi: 10.1136/bmj.c3620.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancer. J Natl Cancer Inst. 2000;92:1081–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–904.CrossRefPubMedGoogle Scholar
  5. 5.
    Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Piura E, Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol. 2011;2011:982425. doi: 10.1155.2011/982425.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.CrossRefGoogle Scholar
  8. 8.
    Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012;33:1319–26.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett. 2013;5:663–8.PubMedGoogle Scholar
  10. 10.
    Lacombe J, Mangé A, Solassol J. Use of autoantibodies to detect the onset of breast cancer. J Immunol Res. 2014;2014:574981. doi: 10.1155/2014/574981.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83:51–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Swa HL, Blackstock WP, Lim LH, Gunaratne J. Quantitative proteomics profiling of murine mammary gland cells unravels impact of annexin-1 on DNA damage response, cell adhesion, and migration. Mol Cell Proteomics. 2012;11:381–93.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Swa HL, Shaik AA, Lim LH, Gunaratne J. Mass spectrometry based quantitative proteomics and integrative network analysis accentuates modulating roles of annexin-1 in mammary tumorigenesis. Proteomics. 2014; [Epub ahead of print].Google Scholar
  14. 14.
    Wang W, Guan S, Sun S, Jin Y, Lee K-H, Chen Y, et al. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Tumour Biol. 2014;35:4901–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Liu T, Song YN, Shi QY, Liu Y, Bai XN, Pang D. Study of circulating antibodies against CD25 and FOXP3 in breast cancer. Tumour Biol. 2014;35:3779–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Araujo TG, Marangoni K, Rocha RM, Maia YC, Araujo GR, Alcântar TM, et al. Dynamic dialog between cytokeratin 18 and annexin A1 in breast cancer: a transcriptional disequilibrium. Acta Histochem. 2014;116:1178–84.CrossRefPubMedGoogle Scholar
  17. 17.
    de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107:6340–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Yom CK, Han W, Kim SW, Kim HS, Shin HC, Chang JN, et al. Clinical significance of annexin A1 expression in breast cancer. J Breast Cancer. 2011;14:262–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yile Huang
    • 1
  • Cong Zhang
    • 2
  • Cairen Chen
    • 1
  • Shilong Sun
    • 2
  • He Zheng
    • 1
  • Shuli Wan
    • 1
  • Qingyong Meng
    • 1
  • Yubin Chen
    • 3
  • Jun Wei
    • 4
  1. 1.School of Clinical Laboratory ScienceGuangdong Medical CollegeDongguanChina
  2. 2.School of Public Health and MH Radiobiology Research UnitJilin UniversityChangchunChina
  3. 3.Department of RadiotherapySecond Hospital of Jilin UniversityChangchunChina
  4. 4.Division of Health ResearchUniversity of the Highlands and Islands, Centre for Health ScienceInvernessUK

Personalised recommendations